Shangfei Wei

Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants.

X. Zhai, Nan Jiang, Ming-juan Guo, 2022, European journal of medicinal chemistry.

Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.

X. Zhai, Daiying Zuo, Ming-juan Guo, 2021, European journal of medicinal chemistry.

Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.

X. Zhai, Tong Li, Ming-juan Guo, 2020, Bioorganic & medicinal chemistry.

Structure-based design of 2,4-diaminopyrimidine derivatives bearing a pyrrolyl group as ALK and ROS1 inhibitors

X. Zhai, Nan Jiang, Daiying Zuo, 2020 .

Continuous Prompt Enhanced Biomedical Entity Normalization

Biao Fu, Shangfei Wei, Z. Lai, 2022, NLPCC.

Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.

X. Zhai, Ming-juan Guo, Shangfei Wei, 2020, Bioorganic & medicinal chemistry.